SCHEDULE: Millennium Entities Disclose 5.1% Stake in Myriad Genetics

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Myriad Genetics, Inc.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 4,748,327 shares of Myriad Genetics, Inc. common stock, representing 5.1% of the class.
• Integrated Core Strategies (US) LLC beneficially owns 4,466,176 shares of Myriad Genetics, Inc. common stock, representing 4.8% of the class.
• The reporting persons are filing as a group, with Millennium Management LLC acting as the general partner for Integrated Holding Group LP, which is the managing member of Integrated Core Strategies (US) LLC.
• Israel A. Englander is identified as the sole voting trustee of the managing member of Millennium Group Management LLC.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Myriad Genetics, Inc.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that directly impacts sentiment positively or negatively for the issuer's operational or financial performance. However, significant institutional ownership can be viewed as a neutral to slightly positive signal by the market.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.

Management Comments

• Gil Raviv, Global General Counsel for Integrated Core Strategies (US) LLC, Millennium Management LLC, and Millennium Group Management LLC, certified that the information set forth in the statement is true, complete, and correct.
• Israel A. Englander certified that the information set forth in the statement is true, complete, and correct.
• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

Myriad Genetics, Inc. operates in the healthcare and biotechnology sector, focusing on genetic testing. The disclosure of a significant stake by Millennium Management LLC, a prominent hedge fund, indicates institutional interest in the company, which is a common occurrence in the publicly traded healthcare industry.

Stakeholder Impact

• Shareholders may note increased institutional ownership, which could be interpreted as a vote of confidence or increased scrutiny from a large investor.

Key Dates

Keywords

Myriad Genetics, Millennium Management, Schedule 13G, beneficial ownership, institutional investor, common stock, healthcare, biotechnology